Equillium, Inc.
EQHealthcare|Biotechnology|US
$1.51
+0.18 (+13.53%)
DCF Value
$0.32
Tangible Book / Share
$0.50
Cash / Share
$0.51
Clinical Trials (5)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05263999 A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) | Graft Versus Host Disease, GVHD | P3 | Terminated | 158 | RCT, Double-blind | Itolizumab, EQ001 Placebo |
| NCT03532958 Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata | Alopecia Areata, Alopecia Totalis | P2 | Withdrawn | — | RCT, Double-blind | BNZ-1, Normal saline |
| NCT05589610 Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata | Alopecia Areata, Alopecia | P2 | Completed | 36 | Open-label | EQ101 |
| NCT04007198 A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled Asthma | Asthma | P1 | Completed | 18 | RCT, Double-blind | EQ001, EQ001 Placebo |
| NCT07869225 A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of EQ504 in Single and Multiple Ascending Doses in Healthy Volunteers | Ulcerative Colitis | P1 | Not Yet Recruiting | 70 | RCT, Double-blind | EQ504, EQ504 Placebo |